In conclusion, we demonstrated that the rare combination of somatic <i>PTEN</i> and <i>TP53</i> mutations in a patient with a metastatic FTC, together with the presence of tumor heterogeneity and genomic instability, might be associated with a high tumor aggressiveness and resistance to treatments. Here, TP53 is linked to neoplasm.